ZM2987A1 - Thiazepine compounds - Google Patents

Thiazepine compounds

Info

Publication number
ZM2987A1
ZM2987A1 ZM29/87A ZM2987A ZM2987A1 ZM 2987 A1 ZM2987 A1 ZM 2987A1 ZM 29/87 A ZM29/87 A ZM 29/87A ZM 2987 A ZM2987 A ZM 2987A ZM 2987 A1 ZM2987 A1 ZM 2987A1
Authority
ZM
Zambia
Prior art keywords
thiazepine compounds
thiazepine
compounds
Prior art date
Application number
ZM29/87A
Other languages
English (en)
Original Assignee
Ici America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10595359&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZM2987(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ici America Inc filed Critical Ici America Inc
Publication of ZM2987A1 publication Critical patent/ZM2987A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16[b, f]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZM29/87A 1986-03-27 1987-03-24 Thiazepine compounds ZM2987A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868607684A GB8607684D0 (en) 1986-03-27 1986-03-27 Thiazepine compounds

Publications (1)

Publication Number Publication Date
ZM2987A1 true ZM2987A1 (en) 1991-02-28

Family

ID=10595359

Family Applications (1)

Application Number Title Priority Date Filing Date
ZM29/87A ZM2987A1 (en) 1986-03-27 1987-03-24 Thiazepine compounds

Country Status (31)

Country Link
US (1) US4879288A (no)
EP (1) EP0240228B1 (no)
JP (1) JPH064606B2 (no)
KR (1) KR900001868B1 (no)
AR (1) AR242198A1 (no)
AT (1) ATE58132T1 (no)
AU (1) AU593336B2 (no)
BG (1) BG61365B2 (no)
CA (1) CA1288428C (no)
CY (2) CY1706A (no)
DD (1) DD259403A5 (no)
DE (3) DE10075016I2 (no)
DK (1) DK174618B1 (no)
ES (1) ES2019379T4 (no)
FI (1) FI86059C (no)
GB (2) GB8607684D0 (no)
GR (1) GR3001061T3 (no)
HK (1) HK85393A (no)
HU (1) HU201062B (no)
IE (1) IE59864B1 (no)
IL (1) IL81923A (no)
LU (1) LU90593I2 (no)
MW (1) MW2087A1 (no)
NL (1) NL980022I2 (no)
NO (2) NO168771C (no)
NZ (1) NZ219788A (no)
PH (1) PH26516A (no)
PT (1) PT84569B (no)
ZA (1) ZA871940B (no)
ZM (1) ZM2987A1 (no)
ZW (1) ZW5787A1 (no)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705574D0 (en) * 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
DE3827447A1 (de) * 1988-08-12 1990-04-26 Basf Ag Polyazofarbstoffe und deren zwischenprodukte
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
GB9109557D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5240927A (en) * 1992-05-19 1993-08-31 Hoechst-Roussel Pharmaceuticals Incorporated Benzo[β]thiophen-3-yl piperazines as antipsychotic agents
JP2000507544A (ja) 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 痛みの治療方法
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
GB9716161D0 (en) * 1997-08-01 1997-10-08 Zeneca Ltd Process
GB9922271D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Formulation
SE0003126D0 (sv) * 2000-09-05 2000-09-05 Astrazeneca Ab Method of treatment
JP2004516271A (ja) * 2000-12-20 2004-06-03 アストラゼネカ・アクチエボラーグ 治療法
JP2004518699A (ja) * 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
EP1795199A3 (en) * 2001-02-06 2007-07-25 AstraZeneca AB Quetiapine for the treatment of substance dependence or substance abuse
US20040023951A1 (en) * 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
ATE503845T1 (de) * 2001-12-10 2011-04-15 Novartis Pharma Gmbh Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
EP1482945A1 (en) 2002-03-20 2004-12-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
KR100707050B1 (ko) 2002-11-28 2007-04-13 에스케이 주식회사 10H-디벤조[b,f][1,4]티아제핀-11-온의 제조방법
WO2004064846A1 (en) * 2003-01-14 2004-08-05 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
CA2516646A1 (en) * 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof
TR200503401T1 (tr) * 2003-03-03 2008-03-21 Hetero Drugs Limited Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
EP1611138A1 (en) * 2003-04-07 2006-01-04 Hetero Drugs Limited A novel crystalline form of dorzolamide hydrochloride
AU2004237951A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
US20060229292A1 (en) * 2005-01-07 2006-10-12 Astrazeneca Ab Method of treating childhood disorders
US20070117789A1 (en) * 2005-11-18 2007-05-24 Astrazeneca Ab Method of treatment
US20090093460A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Compositions
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
US20090093461A1 (en) * 2003-07-02 2009-04-09 Astrazeneca Ab Methods of Treating Anxiety and Mood Disorders
EP1644005B1 (en) * 2003-07-02 2010-08-18 AstraZeneca AB Metabolite of quetiapine
US20060217365A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating mood disorders
US20060252743A1 (en) * 2005-01-07 2006-11-09 Astrazeneca Ab Method of treating sleep disorders
US20060217367A1 (en) * 2004-07-01 2006-09-28 Astrazeneca Ab Method of treating anxiety disorders
ES2223294B2 (es) * 2003-08-08 2005-10-01 Vita Cientifica, S.L. Procedimiento de preparacion de un compuesto farmaceuticamente activo.
US20050080072A1 (en) * 2003-09-01 2005-04-14 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a thiazepine derivative
ATE496038T1 (de) * 2003-09-23 2011-02-15 Fermion Oy Verfahren zur herstellung von quetiapin
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
JP2007534656A (ja) 2003-12-22 2007-11-29 アカディア ファーマシューティカルズ,インコーポレーテッド ムスカリンアゴニストとしてのアミノ置換ジアリール[a,d]シクロヘプテン類似体および精神神経疾患の治療方法
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR101038389B1 (ko) * 2004-06-23 2011-06-01 에스케이바이오팜 주식회사 11-(4-[2-(2-히드록시에톡시)에틸]-1-피페라지닐)-디벤조[b,f][1,4]티아제핀의 제조방법
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
MX2007002309A (es) * 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
WO2006027789A1 (en) * 2004-09-08 2006-03-16 Jubilant Organosys Limited PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US20060063927A1 (en) * 2004-09-22 2006-03-23 Olga Etlin Processes for preparing quetiapine and salts thereof
WO2006035293A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Polymorphic forms of quetiapine hemifumarate
WO2006056772A2 (en) * 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Salts of quetiapine
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
WO2006077602A1 (en) * 2005-01-24 2006-07-27 Ipca Laboratories Limited INDUSTRIAL PREPARATION OF 11-[4-{2-(2-HYDROXYETHOXY ETHYL}-1-PIPERAZINYL] DIBENZO [b,f]-1[1, 4] THIAZEPINE
JP2008528607A (ja) * 2005-01-26 2008-07-31 エラン・ファルマ・インターナショナル・リミテッド 抗精神薬を含む制御調節組成物
ES2234447B1 (es) * 2005-03-07 2006-03-01 Union Quimico-Farmaceutica S.A. Procedimiento para la obtencion de un derivado de 11-(4-sustituido-1-piperazinil)dibenzo(b,f)(1,4)tiazepina.
US20060211686A1 (en) * 2005-03-18 2006-09-21 Abbott Laboratories Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
US7488821B2 (en) * 2005-04-04 2009-02-10 Divi's Laboratories Limited Polymorph of Quetiapine fumarate and a process for its preparation
EP1869007A1 (en) * 2005-04-14 2007-12-26 Teva Pharmaceutical Industries Ltd Process for preparing quetiapine fumarate
CA2605473C (en) 2005-04-21 2013-10-29 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
MX2007013026A (es) * 2005-04-22 2008-01-11 Wyeth Corp Combinaciones terapeuticas para el tratamiento o prevencion de trastornos psicoticos.
JP2008545650A (ja) * 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070072840A1 (en) * 2005-05-30 2007-03-29 Pandya Bhargav Polymorphic forms of quetiapine
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2007004234A1 (en) * 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
GB0516603D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Processes for the preparation of organic compounds useful as serotonin receptor antagonists
US8044038B2 (en) 2005-09-30 2011-10-25 Fermion Oy Crystallization process of quetiapine hemifumarate
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
WO2009151393A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
US8389510B2 (en) * 2005-11-18 2013-03-05 Astrazeneca Ab Crystalline forms
WO2009151392A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US20070155824A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007086079A2 (en) 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
US20070191451A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents
US20070191450A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder
US20070191460A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
WO2007102074A2 (en) * 2006-03-07 2007-09-13 Cadila Healthcare Limited Salts of quetiapine
EP2026790A2 (en) * 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Co-therapy for the treatment of epilepsy and related disorders
EP2041304B1 (en) 2006-06-12 2011-09-07 Hadasit Medical Research Services & Development Limited Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
US20080004260A1 (en) * 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
CZ300451B6 (cs) 2006-07-03 2009-05-20 Farmak, A. S. Zpusob prípravy solí 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanolu (quetiapinu) a jejich cištení
WO2008047340A1 (en) * 2006-10-19 2008-04-24 Mor Research Applications Ltd. Combined therapies of antipsychotic drugs and tetracyclines in the treatment of psychiatric disorders
WO2008066620A2 (en) * 2006-10-20 2008-06-05 Concert Pharmaceuticals Inc. Dibenzothiazepine derivatives
CN101610774B (zh) * 2006-11-03 2012-04-04 萨斯喀彻温大学 治疗脱髓鞘疾病的方法
PT103884A (pt) 2006-11-17 2008-05-19 Astrazeneca Ab Composições de libertação prolongada e métodos para a sua preparação
JP2010510314A (ja) 2006-11-22 2010-04-02 シーサイド セラピューティクス,エルエルシー 精神遅滞、ダウン症候群、脆弱x症候群および自閉症の治療方法
US20100093699A1 (en) * 2006-12-20 2010-04-15 Astrazeneca Ab Compounds and uses thereof - 177
CN101616661A (zh) * 2006-12-20 2009-12-30 阿斯利康(瑞典)有限公司 化合物及其用途
EP2131817A2 (en) 2007-03-09 2009-12-16 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
CN100569761C (zh) * 2007-04-18 2009-12-16 湖南洞庭药业股份有限公司 制备药物纯富马酸喹硫平的生产方法
US8101597B2 (en) * 2007-05-07 2012-01-24 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
HU230144B1 (hu) * 2007-06-12 2015-09-28 Richter Gedeon Nyrt. Eljárás quetiapin előállítására
US20090082334A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched quetiapine
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
US8420807B2 (en) * 2008-01-31 2013-04-16 Fermion Oy Process for the preparation of quetiapine
CA2716080C (en) 2008-02-20 2016-12-13 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090264408A1 (en) * 2008-04-17 2009-10-22 Gulati Inder Extended release dosage forms of quetiapine
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
KR20110019781A (ko) 2008-06-20 2011-02-28 아스트라제네카 아베 디벤조티아제핀 유도체 및 그의 용도
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
EP2309994A2 (en) * 2008-07-01 2011-04-20 Lupin Limited Sustained release pharmaceutical compositions comprising quetiapine
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
AU2008359725A1 (en) * 2008-07-24 2010-01-28 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
EA018638B1 (ru) * 2008-08-01 2013-09-30 Крка, Товарна Здравил, Д. Д., Ново Место Композиция кветиапина
EP2153834A3 (en) 2008-08-07 2010-02-24 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
DE102008046650A1 (de) * 2008-09-10 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Quetiapin enthaltende Retardtablette
JP2012502915A (ja) 2008-09-15 2012-02-02 バイオビスタ インコーポレイテッド てんかんを治療する組成物及び方法
WO2010082220A2 (en) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof
WO2010089259A2 (en) 2009-02-04 2010-08-12 Woerwag R&D Gmbh Sustained release composition containing quetiapine
JP2012519683A (ja) 2009-03-04 2012-08-30 ランバクシー ラボラトリーズ リミテッド フマル酸クエチアピンの調製方法
EP2233130A1 (en) 2009-03-23 2010-09-29 Genepharm (Europe) Trading Limited A sustained release oral composition of an antipsychotic agent
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
US8252801B1 (en) 2009-06-03 2012-08-28 Abbott Laboratories Treatment of schizophrenia and related disorders
AU2010336981B2 (en) 2009-12-31 2014-04-10 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
EP2544536B1 (en) 2010-03-11 2018-12-12 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
PL2608670T3 (pl) 2010-08-23 2019-05-31 Alkermes Pharma Ireland Ltd Sposoby leczenia przyrostu masy ciała wywołanego neuroleptykiem
TR201008261A1 (tr) 2010-10-08 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Kontrollü salım gerçekleştiren ketiapin formülasyonları
WO2012064349A1 (en) 2010-11-09 2012-05-18 Forest Carl A Sleep aid composition and method
DK3034079T3 (en) 2010-11-15 2018-02-05 Agenebio Inc PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
TR201104977A1 (tr) 2011-05-23 2012-12-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım gerçekleştiren kaplamaya sahip ketiapin formülasyonu.
WO2013074048A2 (en) 2011-08-08 2013-05-23 Mahmut Bilgic Tablet forms comprising quetiapine fumarate
CN102391208A (zh) * 2011-10-25 2012-03-28 湖南洞庭药业股份有限公司 富马酸喹硫平的新晶形i及其制备方法
WO2013095312A1 (en) 2011-12-19 2013-06-27 Mahmut Bilgic Formulations comprising quetiapine fumarate
WO2013100879A1 (en) 2011-12-27 2013-07-04 Mahmut Bilgic Pharmaceutical compositions comprising quetiapine
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
EP2848244A1 (en) 2013-09-16 2015-03-18 Yildiz Özsoy Erginer Extended release tablet formulations of quetiapine
MX2016007808A (es) 2013-12-20 2016-09-07 Agenebio Inc Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro congnitivo.
CN104016945B (zh) * 2014-05-27 2016-06-29 渭南畅通药化科技有限公司 一种半富马酸喹硫平的制备方法
MX2020013374A (es) 2015-06-19 2022-05-06 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020026062B1 (pt) 2018-06-19 2023-04-04 Agenebio, Inc Compostos derivados de benzodiazepina ou um sal farmaceuticamente aceitavel, isômero ou combinação dos mesmos, composição farmacêutica compreendendo os mesmos e usos dos mesmos para o tratamento de comprometimento cognitivo, câncer cerebral e psicose da doença de parkinson
WO2020025579A1 (en) 2018-07-31 2020-02-06 Medichem, S.A. Solid dosage form of quetiapine fumarate
WO2022058989A1 (en) 2020-09-21 2022-03-24 Sun Pharmaceutical Industries Limited Multi-particulate pharmaceutical composition of quetiapine
CN113698363A (zh) * 2021-09-15 2021-11-26 苏州敬业医药化工有限公司 一种11-哌嗪-二苯并[b,f][1,4]硫氮杂卓盐酸盐的纯化方法
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3389139A (en) * 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
FR111F (no) * 1964-03-27
FR90378E (no) * 1965-03-26 1968-02-14
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
CH539044A (de) * 1967-10-06 1973-08-31 Gnii Orch Poluproduktov I Kras Verfahren zur Herstellung quaternärer Ammoniumsalze von 1,3-Bis-(aminomethyl)-imidazolidonen
US3928356A (en) * 1967-10-06 1975-12-23 Fujisawa Pharmaceutical Co 10-{8 4-({107 -Hydroxy alkyl)-1-piperazimyl{9 -dibenzo (h,f) oxofins and thiepins and acetyl esters thereof
GB1262509A (en) * 1969-06-20 1972-02-02 Science Union & Cie New tricyclic derivatives and process for their preparation
CA918659A (en) * 1969-07-31 1973-01-09 Yoshitomi Pharmaceutical Industries 11-(4-substituted-1-piperazinyl)-dibenzo (b,f) (1,4) thiazepines
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
BE792426A (fr) * 1971-12-09 1973-06-07 Wander Ag Dr A Nouveaux derives de la dibenzo(b,f)(1,4)thiazepine, leur preparation etleur application comme medicaments
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569731A5 (no) * 1972-04-04 1975-11-28 Wander Ag Dr A
CH624682A5 (no) * 1976-11-10 1981-08-14 Sandoz Ag
US4096261A (en) * 1977-02-23 1978-06-20 Abbott Laboratories Dibenzodiazepines
US4097597A (en) * 1977-02-23 1978-06-27 Abbott Laboratories Dibenzo b,e! 1,4!diazepines

Also Published As

Publication number Publication date
JPS638378A (ja) 1988-01-14
DE10075017I1 (de) 2000-09-21
HUT47568A (en) 1989-03-28
PH26516A (en) 1992-08-07
IE870700L (en) 1987-09-27
LU90593I2 (fr) 2000-08-07
FI86059C (fi) 1992-07-10
ES2019379T4 (es) 2015-08-12
NO2001009I1 (no) 2001-06-25
HK85393A (en) 1993-08-27
NZ219788A (en) 1990-02-26
DK158587A (da) 1987-09-28
MW2087A1 (en) 1987-11-11
EP0240228A1 (en) 1987-10-07
KR900001868B1 (ko) 1990-03-26
GB8706949D0 (en) 1987-04-29
BG61365B2 (bg) 1997-06-30
CY98045I1 (el) 2010-07-28
IL81923A0 (en) 1987-10-20
DE10075016I2 (de) 2002-10-10
AR242198A1 (es) 1993-03-31
FI871137A0 (fi) 1987-03-16
DE3765969D1 (en) 1990-12-13
CA1288428C (en) 1991-09-03
AU593336B2 (en) 1990-02-08
GR3001061T3 (en) 1992-03-20
ATE58132T1 (de) 1990-11-15
JPH064606B2 (ja) 1994-01-19
NO871267L (no) 1987-09-28
PT84569A (en) 1987-04-01
ZA871940B (en) 1987-11-25
CY98045I2 (el) 2010-07-28
NO168771B (no) 1991-12-23
FI871137A (fi) 1987-09-28
DD259403A5 (de) 1988-08-24
IL81923A (en) 1991-03-10
EP0240228B1 (en) 1990-11-07
NL980022I2 (nl) 1998-11-02
NO168771C (no) 1992-04-01
ZW5787A1 (en) 1988-11-02
IE59864B1 (en) 1994-04-20
AU7045987A (en) 1987-10-01
GB8607684D0 (en) 1986-04-30
HU201062B (en) 1990-09-28
ES2019379B3 (es) 1991-06-16
US4879288A (en) 1989-11-07
NO871267D0 (no) 1987-03-26
DK174618B1 (da) 2003-07-21
CY1706A (en) 1994-01-14
KR870008879A (ko) 1987-10-21
FI86059B (fi) 1992-03-31
PT84569B (pt) 1989-11-30
DK158587D0 (da) 1987-03-27
NL980022I1 (nl) 1998-10-01

Similar Documents

Publication Publication Date Title
AR242198A1 (es) Procedimiento para la preparacion del compuesto 11-(4¡2-(2-hidroxietoxi)etil¿-1-piperazinil)dibenzo(b,f)(1,4)-tiazepina.
GB2188317B (en) 4-oxo-quinoline compounds
GB8601796D0 (en) Compounds
AR245099A1 (es) N-neoalcanamidas de alquilo inferior utiles como repelentes de insectos, composiciones domesticas, detergentes, repelentes y perfumes que las contienen.
GB8610909D0 (en) Compounds
GB8600651D0 (en) Compounds
EP0238443A3 (en) Dicyanobenzanthrone compounds
GB8601371D0 (en) Compounds
GB8600978D0 (en) Compounds
GB8600979D0 (en) Compounds
GB8602236D0 (en) Compounds
GB8600262D0 (en) Compounds
GB8600261D0 (en) Compounds
GB8600980D0 (en) Compounds
GB8601121D0 (en) Compounds
GB8600649D0 (en) Compounds
GB8601122D0 (en) Compounds
GB8612522D0 (en) Compounds
GB8600648D0 (en) Compounds
GB8600612D0 (en) Compounds
GB8600643D0 (en) Compounds
GB8600977D0 (en) Compounds
GB8602169D0 (en) Compounds
GB8602160D0 (en) Iminophenyl compounds
GB8602170D0 (en) Compounds